Biotechnology 

    Latest News Releases
 
*DISCLAIMER*: Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, Frankly and this Station make no warranties or representations in connection therewith.
HONEYWELL, JOHNSON MATTHEY, GIDARA ENERGY AND SAMSUNG E&A FORM SAF TECHNOLOGY ALLIANCE

Honeywell (NASDAQ: HON), Johnson Matthey, GIDARA Energy and SAMSUNG E&A today announced the formation of a strategic technology alliance to bring a groundbreaking end-to-end global solution to market for producing...

HONEYWELL, JOHNSON MATTHEY, GIDARA ENERGY AND SAMSUNG E&A FORM SAF TECHNOLOGY ALLIANCE
Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities

Tsingke Biotech recently participated in TIDES USA 2025, the leading international event for oligonucleotide and peptide therapeutics, held in San Diego from May 19 to 22. As a repeat exhibitor, Tsingke highlighted its...

Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities
Innovent's IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular...

Innovent's IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and...

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding

Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256, has been selected for funding by...

Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding
Dynavax Comments on Glass Lewis Recommendation

Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today commented on a report published by Glass,...

Dynavax Comments on Glass Lewis Recommendation
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction

With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo.

Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
UMA AND MILA: NEW SEATING DUO FROM BOSS DESIGN BRINGS COMFORT, ELEGANCE AND SUSTAINABILITY

Boss Design is pleased to announce Uma and Mila, two new seating lines crafted for next-level comfort and designed to bring eye-catching elegance across workspace and hospitality settings – both manufactured with a focus...

UMA AND MILA: NEW SEATING DUO FROM BOSS DESIGN BRINGS COMFORT, ELEGANCE AND SUSTAINABILITY
Aitia and Gustave Roussy Join Forces to Identify the Fundamental Biological Causes of Multiple Human Cancers

Aitia, the leader in computationally discovering and applying new knowledge of biological causes of disease to pharmaceutical discovery and development, today announced a collaboration with Gustave Roussy, the premier...

Aitia and Gustave Roussy Join Forces to Identify the Fundamental Biological Causes of Multiple Human Cancers
Avista Healthcare Partners Acquires EBI from Highridge Medical, Marking 50th Platform Investment

Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced its acquisition of EBI, the bone healing division of Highridge Medical ("EBI" or the "Company").

Avista Healthcare Partners Acquires EBI from Highridge Medical, Marking 50th Platform Investment
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today announced the completion of enrollment for its open-label Phase 2a clinical trial evaluating HT-6184...

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
Repertoire Immune Medicines Appoints Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer and Advances TCR Bispecific Development Candidate Toward the Clinic

Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced the appointment of Robert Andtbacka, MD, CM, FACS, FRCSC, as...

Repertoire Immune Medicines Appoints Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer and Advances TCR Bispecific Development Candidate Toward the Clinic
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific...

Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular...

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
BioVaxys Issues Corporate Update

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives including the integration and disposition of assets acquired in February 2024...

BioVaxys Issues Corporate Update
Akadeum Life Sciences Lands Major Investment to Fuel Growth in Cell and Gene Therapy

Akadeum Life Sciences, a pioneer in buoyancy-based cell separation technology, today announced the successful close of a $20 million+ financing round. The round was led by Michigan Capital Network, with strong...

Akadeum Life Sciences Lands Major Investment to Fuel Growth in Cell and Gene Therapy
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today...

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
Big4Bio Launches 'AMPLIFY' to Supercharge Life Sciences Visibility

Big4Bio, the premier aggregator of life sciences news and industry developments, has launched AMPLIFY - a premium membership program designed to provide powerful, integrated distribution solutions to magnify visibility and...

Big4Bio Launches 'AMPLIFY' to Supercharge Life Sciences Visibility
ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis

ThinkCyte, a life science company pioneering advanced AI-powered cell analysis and sorting technologies, today announced the pre-commercial launch of MorphoScan Cloud, its new cloud-based platform designed for flexible...

ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis
H World Group Releases 2024 Sustainability Report, Advancing Sustainable Development through Service Innovation and Green Operations

H World Group Limited (NASDAQ:HTHT) (HK:01179), a leading hospitality group, has released its 2024 Sustainability Report, reaffirming its commitment to  sustainable growth powered by innovation, inclusion, and bold...

H World Group Releases 2024 Sustainability Report, Advancing Sustainable Development through Service Innovation and Green Operations
Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach

Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized medicine, and unlocking unprecedented opportunities to accelerate drug...

Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach
MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY

Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular data for predictive biology, today announces new Series A financing. The round was led by Lewis & Clark Partners and OMX Ventures,...

MATTERWORKS INC. SECURES SERIES A FUNDING TO ADVANCE MACHINE INTELLIGENCE FOR PREDICTIVE BIOLOGY
AmplifyeP24 Can Double Protein Absorption with One Daily Capsule

Amplifye, a biotechnology company specializing in enhancing protein nutrition through the development of proprietary enzymes, today announces the launch of its first consumer product, amplifyeP24. Without changing the...

AmplifyeP24 Can Double Protein Absorption with One Daily Capsule
Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach

Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US-based immuno-oncology company developing next-generation therapeutics for...

Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach
Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations at the GBA1 Meeting 2025

Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's...

Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations at the GBA1 Meeting 2025
Montrose Environmental Group Releases 2024 Sustainability Report Highlighting Climate Commitments, Innovation and Client Impact

Montrose Environmental Group, Inc. (NYSE: MEG) is on a mission to help protect the air we breathe, the water we drink, and the soil that feeds us to enhance environmental stewardship while supporting economic development....

Montrose Environmental Group Releases 2024 Sustainability Report Highlighting Climate Commitments, Innovation and Client Impact
Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy

Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced it has raised $56 million in Series C financing. The new financing will be used to expand commercialization...

Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in...

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025...

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies

Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus' today announced its entry into the global biologics contract development and manufacturing organization (CDMO)...

Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed on...

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview
Genprex to Participate at BIO 2025 International Convention

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be...

Genprex to Participate at BIO 2025 International Convention
Albemarle Publishes 2024 Sustainability Report, Updates Efforts to Reduce Carbon Footprint, Manage Freshwater Responsibly and Support Customers' Sustainability Goals

Albemarle Corporation (NYSE: ALB), a global leader in providing essential elements for mobility, energy, connectivity, and health, today published its 2024 Sustainability Report. Entitled Values-Led, Purpose-Driven, the...

Albemarle Publishes 2024 Sustainability Report, Updates Efforts to Reduce Carbon Footprint, Manage Freshwater Responsibly and Support Customers' Sustainability Goals
Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase 1 trial for EBC-129 at...

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
AmphiStar and Kensing Announce Strategic Partnership to Bring Upcycled Biosurfactants to the North American Personal Care Market

Belgian biotech innovator AmphiStar, a pioneer in 100% upcycled microbial biosurfactants and Kensing, a leading North American producer of high-purity surfactants, and the global leader in upcycled plant-based vitamin E...

AmphiStar and Kensing Announce Strategic Partnership to Bring Upcycled Biosurfactants to the North American Personal Care Market
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS

XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New...

XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS
REMADE? Announces Request for Information for New York State Waste Tire Program

The REMADE? Institute, a division of the Sustainable Manufacturing Innovation Alliance Corp., has issued a Request for Information (RFI) to solicit input from stakeholders to inform the New York State (NYS) Waste Tire...

REMADE? Announces Request for Information for New York State Waste Tire Program
ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody 'IMC-002' at ASCO 2025

ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with lenvatinib for...

ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody 'IMC-002' at ASCO 2025
Expansion of Frontage Laboratories Continues with Launch of New State-of-the-Art CRDMO Facility in Exton, PA

Frontage Laboratories, Inc. officially unveiled its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility during a grand open house event held on May 22, 2025, at its campus in Exton,...

Expansion of Frontage Laboratories Continues with Launch of New State-of-the-Art CRDMO Facility in Exton, PA
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read sequencing...

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
Ecobat Completes Sale of European Battery Distribution Business to Endless LLP

Ecobat, a global leader in battery recycling, today announced the successful completion of the sale of its European battery distribution business to Endless LLP, a UK-based private equity firm.

Ecobat Completes Sale of European Battery Distribution Business to Endless LLP
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part...

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
Join the Manufacturing Digitalization Expo 2025 in Shanghai, June 17-19!

The Manufacturing Digitalization Expo (Shanghai), organized by Digit Events Ltd., will hold its grand opening from 17 to 19 June, 2025, at the Shanghai New International Expo Centre. World of Digitalization (WOD), a...

Join the Manufacturing Digitalization Expo 2025 in Shanghai, June 17-19!
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161),...

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
Oxford Cancer Biomarkers partners with Mira Precision Health to advance its ToxNav® test for predicting patient toxicity to 5FU/capecitabine treatment in the USA

Following the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira...

Oxford Cancer Biomarkers partners with Mira Precision Health to advance its ToxNav® test for predicting patient toxicity to 5FU/capecitabine treatment in the USA
Arthrosi Announces Multiple Presentations at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve...

Arthrosi Announces Multiple Presentations at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025
Lilly presents first clinical data for its investigational, next-generation FRa targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRa) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity...

Lilly presents first clinical data for its investigational, next-generation FRa targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 (phentolamine ophthalmic solution 0.75%) in treating significant,...

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
Diakonos Oncology Presents Promising Phase I Results of Dubodencel (DOC1021) for the Treatment of Glioblastoma at the ASCO 2025 Annual Meeting

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its Phase I clinical trial...

Diakonos Oncology Presents Promising Phase I Results of Dubodencel (DOC1021) for the Treatment of Glioblastoma at the ASCO 2025 Annual Meeting
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of...

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the...

Immunic to Participate in Investor, Scientific and Industry Conferences in June
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI...

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2,...

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody,...

Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world's first circular RNA drug being administrated in patients

Shanghai CirCode Biomed Co. Ltd. (CirCode), an innovative biotech company pioneering circular RNA therapies, recently announced that its leading pipeline HM2002 received Investigational New Drug (IND) clearance from the US...

CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world's first circular RNA drug being administrated in patients
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an...

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Darmiyan Receives FDA Approval for Post-Market Surveillance Study of BrainSee, the First-in-Class Clinical Test for Predicting Risk of Progression to Clinical Alzheimer's Disease

Darmiyan, Inc., a leading brain health technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's post-market surveillance study for BrainSee, its groundbreaking...

Darmiyan Receives FDA Approval for Post-Market Surveillance Study of BrainSee, the First-in-Class Clinical Test for Predicting Risk of Progression to Clinical Alzheimer's Disease
Zenagen Named Top Selling Thinning Hair Product in North American Salons by Kline Research

Zenagen, the hair wellness brand disrupting the hair loss market with its clinically developed, plant-powered technology, is proud to announce that its flagship Revolve Shampoo for Women has officially been named the #1...

Zenagen Named Top Selling Thinning Hair Product in North American Salons by Kline Research
BLUETTI and Footprint Project Forge Partnership to Bring Essential Clean Power Lifelines to Storm-Hit Communities

BLUETTI, a global leader in clean energy solutions, today announced a strategic partnership with the non-profit organization Footprint Project to tackle the upcoming hurricane and storm season head-on.

BLUETTI and Footprint Project Forge Partnership to Bring Essential Clean Power Lifelines to Storm-Hit Communities
Sun Pharma Completes its Acquisition of Checkpoint Therapeutics

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion...

Sun Pharma Completes its Acquisition of Checkpoint Therapeutics
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001

Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced that it has completed the initial dosing in healthy...

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001
Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting

Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, is presenting results of two studies...

Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at the 2025 ASCO Annual Meeting
ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced today that a Trial in Progress poster for its first-in-human, Phase 1a/1b clinical trial of IMGS-001 will be...

ImmunoGenesis to present IMGS-001 Phase 1a/1b Clinical Study Updates at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"

AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer through a campaign called "Striking Out Cancer" which starts today when the Chicago Cubs play the Cincinnati...

AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expand Use of Innovative Dendritic Cell Platform for Studies in Other Indications

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced the closing of a $20 million private placement of...

Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expand Use of Innovative Dendritic Cell Platform for Studies in Other Indications
Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and...

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 29, 2025, the Compensation Committee of...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Elegoo Expands CSR Programs for Social Inclusion, Marking 10 Years of Empowering Creators

Elegoo, a rapidly developing brand in global smart manufacturing, has expanded its corporate social responsibility (CSR) programs with the launch of ELEGOO Empowers, a new initiative promoting social inclusion, STEM...

Elegoo Expands CSR Programs for Social Inclusion, Marking 10 Years of Empowering Creators
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that...

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance Corporation ("Horizon") have executed a follow-on Amendment...

BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today announced they have entered into an exclusive license agreement for XNW27011, a...

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
Flor de Caña and Danil Nevsky launched Sustainable Cocktail Tour in the U.S.

Flor de Caña, the renowned premium rum brand, and Danil Nevsky, recognized as the #2 World's Most Influential Bartender, recently joined forces to launch a high-profile sustainable guest bartending tour across the...

Flor de Caña and Danil Nevsky launched Sustainable Cocktail Tour in the U.S.
Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration

Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central laboratory services. The two parties will jointly build a full-chain...

Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration
Amyris Takes Full Ownership of Brazilian Industrial Fermentation Plant and Invests in Completion of Fourth Precision Fermentation Line

Amyris, Inc., a vertically integrated synthetic biology company and leading innovator in the field of industrial biotechnology, today announced that it has acquired Ingredion's 31% stake in the RealSweet Joint Venture...

Amyris Takes Full Ownership of Brazilian Industrial Fermentation Plant and Invests in Completion of Fourth Precision Fermentation Line
RevivBio Welcomes Dr. Ronald Meeusen to Board of Directors, Strengthening Leadership in Biotech Innovation and Commercialization

RevivBio, a trailblazing biotech company Redefining Biologics and Biosensors development, welcomes Dr. Ron Meeusen to its Board of Directors. Dr. Meeusen is a renowned leader in biotechnology, with a distinguished track...

RevivBio Welcomes Dr. Ronald Meeusen to Board of Directors, Strengthening Leadership in Biotech Innovation and Commercialization
Vizgen and Hamamatsu Partner to Streamline Spatial Biology Workflows

Vizgen, Inc., a life sciences company advancing spatial multi-omics, today announced a strategic partnership with Hamamatsu Photonics K.K., a global leader in optical imaging technology. This collaboration integrates...

Vizgen and Hamamatsu Partner to Streamline Spatial Biology Workflows
RS Group earns three new ESG accolades

RS, a high-service global product and service solutions provider for industrial customers, continues to achieve ambitious environmental, social, and governance (ESG) goals and has already earned three new accolades in...

RS Group earns three new ESG accolades
Mapmygenome cements global leadership in Genomics with strategic acquisition of Canada's Microbiome Insights

Mapmygenome, an AI-driven leader in genomics and personalized health, announced the strategic acquisition of Microbiome Insights, a global leader in microbial sequencing. The acquisition includes Microbiome Insights'...

Mapmygenome cements global leadership in Genomics with strategic acquisition of Canada's Microbiome Insights
Blackbaud's 2024 Impact Report Highlights Continued Commitment to Corporate Social Responsibility

Blackbaud (NASDAQ: BLKB), the leading provider of software for powering social impact, today released its 2024 Impact Report, sharing how the company has advanced its environmental, social and governance priorities in the...

Blackbaud's 2024 Impact Report Highlights Continued Commitment to Corporate Social Responsibility
Facet Life Sciences Announces Partnership with Nucleus as Official Regulatory Partner

Facet Life Sciences specializes in guiding life science companies through the complex journey of drug, biologic, and medical device development and registration with the US FDA. Facet is pleased to announce the...

Facet Life Sciences Announces Partnership with Nucleus as Official Regulatory Partner
Dx&Vx Accelerates Development of Universal COVID-19 Vaccine

Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide...

Dx&Vx Accelerates Development of Universal COVID-19 Vaccine
Made Scientific Powers Late-Phase and Commercial Cell Therapy Manufacturing with 12,000 sq. ft. Expansion in Princeton, NJ GMP Facility

Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO), today announced a significant expansion of its Princeton, New Jersey facility to meet increasing demand from late-phase...

Made Scientific Powers Late-Phase and Commercial Cell Therapy Manufacturing with 12,000 sq. ft. Expansion in Princeton, NJ GMP Facility
Florida Cancer Specialists & Research Institute Driving Global Progress in Cancer Care Discoveries

Findings from 34 clinical research studies conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) are among the groundbreaking scientific advances in cancer care that will be featured as oncology...

Florida Cancer Specialists & Research Institute Driving Global Progress in Cancer Care Discoveries
Bionique Testing Laboratories and Cellipont Bioservices Partner to Accelerate Adoption of Rapid Mycoplasma Testing in Cell and Gene Therapy Manufacturing

Bionique Testing Laboratories, a global leader in mycoplasma testing services and part of the Asahi Kasei group, and Cellipont Bioservices, a premier Contract Development and Manufacturing Organization (CDMO) specializing...

Bionique Testing Laboratories and Cellipont Bioservices Partner to Accelerate Adoption of Rapid Mycoplasma Testing in Cell and Gene Therapy Manufacturing
Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting

Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three abstracts featuring new clinical data from tumor-infiltrating lymphocytes (TIL) therapies will...

Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting
RBL LLC Announces Launch of Sentinel BioTherapeutics at the 2025 ASCO Annual Meeting

RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical technologies from Rice University, today announced the launch of Sentinel BioTherapeutics at the...

RBL LLC Announces Launch of Sentinel BioTherapeutics at the 2025 ASCO Annual Meeting
Diakonos Oncology to Present Phase I Results of Dubodencel (DOC1021), a Double-Loaded Dendritic Cell Therapy for Glioblastoma, at the ASCO 2025 Annual Meeting

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced that it will present new clinical data at the 2025...

Diakonos Oncology to Present Phase I Results of Dubodencel (DOC1021), a Double-Loaded Dendritic Cell Therapy for Glioblastoma, at the ASCO 2025 Annual Meeting
AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation

AccurEdit Therapeutics today announced that its internally developed in vivo gene editing therapy ART001 has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration...

AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025

Rona Therapeutics, a global leading RNA therapy company, today announced preclinical data for its self-developed RNA interference (RNAi) therapy RN026 at the National Lipid Association (NLA) Annual Scientific...

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025
Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval

Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful efficacy signals in a subgroup of participants with slow disease...

Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
CraniUS Therapeutics Awarded Maryland Tech Council's "2025 Emerging Life Sciences Company of the Year"

CraniUS Therapeutics, a cutting-edge medical device company advancing intracranial drug delivery, is proud to announce it has been voted the "2025 Emerging Life Sciences Company of the Year" by the Maryland Tech Council...

CraniUS Therapeutics Awarded Maryland Tech Council's "2025 Emerging Life Sciences Company of the Year"
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has been...

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today...

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
tHIS ASEAN 2025 to Debut in Kuala Lumpur, Uniting Southeast Asia's Healthcare Powerhouses

The Health Industry Series - ASEAN (tHIS ASEAN 2025), a groundbreaking event aimed at integrating healthcare resources across Southeast Asia, is set to take place in Kuala Lumpur during June 9-11. Co-located with the APHM...

tHIS ASEAN 2025 to Debut in Kuala Lumpur, Uniting Southeast Asia's Healthcare Powerhouses
Stealth BioTherapeutics Announces "Path Forward" Despite Disappointing Delay for Ultra-rare Barth Syndrome

Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial...

Stealth BioTherapeutics Announces "Path Forward" Despite Disappointing Delay for Ultra-rare Barth Syndrome
China's HER2-Targeted ADC Trastuzumab Rezetecan Gains NMPA Approval for HER2-Mutant NSCLC

The National Medical Products Administration has recently granted approval for Trastuzumab rezetecan, China's first domestically developed antibody-drug conjugate (ADC), for treatment of adult patients with...

China's HER2-Targeted ADC Trastuzumab Rezetecan Gains NMPA Approval for HER2-Mutant NSCLC
Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA

On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed innovative...

Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA
Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med Investment Forum 2025 in Abu Dhabi

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that target the innate immune system, announces that CEO Dr. David Bearss will serve as keynote speaker at the Med Investment Forum 2025....

Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med Investment Forum 2025 in Abu Dhabi
Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD)

Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company developing innovative, best-in-class new chemical entities (NCEs) that transform the treatment paradigm for psychiatric diseases, today announced Phase 2a...

Gilgamesh Pharmaceuticals Announces Positive Topline Phase 2a Results for GM-2505 in Major Depressive Disorder (MDD)
Novel Gene Therapy Offers Hope for Non-Muscle Invasive Bladder Cancer (NMIBC) Patients

Novel Gene Therapy Offers Hope for Non-Muscle Invasive Bladder Cancer (NMIBC) Patients

Lifestyle Today Show - May 17, 2025

Lifestyle Today Show - May 17, 2025

Lifestyle Today Show - May 3, 2025

Lifestyle Today Show - May 3, 2025

Lifestyle Today Show - April 21, 2025

Lifestyle Today Show - April 21, 2025

Lifestyle Today Show - April 12, 2025

Lifestyle Today Show - April 12, 2025

Lifestyle Today Show - March 22, 2025

Lifestyle Today Show - March 22, 2025